Oncology Roadmap

Give Your Team Access to the Most Comprehensive Oncology Forecast Ever Created

Cutting Edge Information's new report, Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013, explores the fiercely competitive oncology market in a way that no other available forecast can match.

Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever - pulling together data from our own proprietary PharmaEdge databases, along with hundreds of additional public and private databases worldwide.

Give your brand team all the oncology market research it needs to make critical product decisions!

Key Questions This Report Will Answer:

• Which drugs will make the most money in the next five years?
• Which drug classes are poised for exponential growth?
• Whose portfolio will allow them to jump out in front of the oncology market?
• How much do brand teams spend in key areas of commercialization?

• Chapter 1: Drug Class Analysis
• Antineoplastics (79)
  • Alkylating Agents (9)
  • Antimetabolites (8)
  • Antimitotics (11)
  • Cytotoxic Antibiotics (5)
  • Hormones (10)
  • Tyrosine Kinase Inhibitors (20)
  • Monoclonal Antibodies (16)
• Immunostimulants (9)
• Other Cancer Treatments (32)
• Adjunct Treatments (16)
• Chapter 2: Cancer Indication Market Analysis
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Lung Cancer
  • Prostate Cancer
• Chapter 3: Company Profiles
  • Amgen
  • AstraZeneca
  • BristolMyersSquibb
  • Celgene
  • Eli Lilly
  • GlaxoSmithKline
  • ImClone
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi-Aventis
  • Schering-Plough